Pyrazoline-based mycobactin analogues as MAO-inhibitors

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• 3,5-Diaryl carbothioamide pyrazolines, designed as mycobactin analogs, demonstrated potent antitubercular activity.
• Clinical issues with Linezolid, an antibiotic with monoamine oxidase (MAO) inhibitory activity, necessitate evaluating related compounds for MAO inhibition.
• Pyrazolines are known for antidepressant and MAO inhibitory properties.

Purpose of the Study:

• To assess the MAO-A and MAO-B inhibitory activity of a pilot library of 32 antitubercular pyrazoline compounds.
• To guide the design of antitubercular agents with reduced MAO inhibitory effects.
• To identify selective MAO-B inhibitors for potential neurodegenerative disorder treatment.

Main Methods:

• Enzyme inhibition assays were performed on rat liver MAO-A and MAO-B isoforms.
• Thirty-two synthesized pyrazoline compounds were screened for their inhibitory profiles.
• Molecular docking studies were conducted using human MAO isoforms.

Main Results:

• The 32 analyzed compounds exhibited a range of activities, from selective to nonselective inhibition of MAO-A and MAO-B.
• Compounds 11, 14, and 16, previously identified as antitubercular agents, were found to be selective MAO-B inhibitors.
• Docking studies indicated that compound 11 interacts with the catalytic sites of both human MAO isoforms, suggesting nonselective inhibition.

Conclusions:

• Specific pyrazoline derivatives show selective MAO-B inhibition, indicating potential therapeutic applications in neurodegenerative diseases.
• The study provides a basis for designing novel antitubercular drugs with minimized MAO-related side effects.
• Compound 11's interaction profile suggests its potential as a nonselective human MAO inhibitor.